Letters to the Editor
and 9a,11b-prostaglandin F 2 overproduction in aspirinexacerbated respiratory disease To the Editor:
Aspirin-exacerbated respiratory disease (AERD) is a distinct phenotype of asthma characterized by sensitivity to aspirin and nonsteroidal anti-inflammatory drugs, nasal polyposis, mast cell activation, 1 and overproduction of cysteinyl leukotrienes. 2, 3 AERD is an important clinical issue because it is strongly related to severe asthma. 4 Some studies suggest that omalizumab is efficacious in patients with severe allergic asthma and other allergic diseases. 5 Markers of T H 2-driven inflammation, including fractional exhaled nitric oxide, peripheral blood eosinophil counts, and serum periostin, have been identified as candidate predictors of omalizumab treatment 6 ; however, data demonstrating that omalizumab improves other inflammatory biomarkers are scarce. Because AERD causes mast cell activation 7 and serious eosinophilic airway inflammation, 8 the effects of omalizumab may be different from those usually observed in severe asthma. Here, the clinical efficacy of omalizumab against AERD is described, and urinary markers of mast cell activation, leukotriene E 4 (LTE 4 ) and prostaglandin D 2 metabolite 9a,11bprostaglandin F 2 (PGD 2 M), were evaluated.
A total of 21 adults with AERD initiated omalizumab treatment at Sagamihara National Hospital in Japan between July 2009 and September 2013. The Ethics Committee of Sagamihara National Hospital approved this study. All patients provided written informed consent. AERD was diagnosed by a systemic aspirin provocation test. All patients had 1 or more positive results in skin or serum-specific IgE tests for common environmental allergens. Patients had been on their usual asthma treatment for at least 12 months before enrollment, but had not previously received omalizumab.
Urinary concentrations of LTE 4 and PGD 2 M, peripheral blood eosinophil counts, respiratory function, and scores for nasal (congestion, anterior rhinorrhea, and anosmia) and asthma-related (dyspnea, wheezing, and cough) symptoms were assessed at enrollment and after 12 months of omalizumab. The number of exacerbations and hospitalizations, and daily corticosteroid dose during the 12 months before enrollment, was compared with those after 12 months of omalizumab treatment. LTE 4 and PGD 2 M were quantified from spot urine samples using enzyme immunoassay after purification with high-performance liquid chromatography, as described previously. 9 The visual analog scale was used to evaluate nasal and asthma-related symptoms. Asthma exacerbation was defined as emergency medical visits, unscheduled doctor's visits, or the need for additional oral or intravenous steroid therapy. After 12 months of omalizumab treatment, physicians used the Global Evaluation of Treatment Effectiveness to classify responders and nonresponders. Omalizumab dosages were individualized according to body weight and serum IgE level, with administration at 2-or 4-week intervals for a minimum dose of 0.016 mg/kg/IgE (IU/mL). Significance testing was performed using the Wilcoxon signed rank test or Mann-Whitney U test for continuous variables and the Fisher exact test for categorical variables.
The study population comprised 21 patients, 3 men and 18 women, with a median age of 60.0 years (interquartile range [IQR], 49.0-64.0 years), a median asthma onset age of 38.0 years (IQR, 23.5-46.5 years), and a median serum IgE level of 77.3 IU/mL (IQR, 53.9-195.0 IU/mL) (see Table E1 in this article's Online Repository at www.jacionline.org). Among the 21 patients, 16 (76.2%) had received systemic corticosteroid therapy at the time of enrollment. During the 12 months before omalizumab treatment, 14 of 21 patients (66.7%) experienced 3 or more asthma exacerbations (median, 5.0 [IQR, 2.0-7.5]) and 6 of 21 patients (28.6%) had at least 1 hospital admission because of an exacerbation (median, 0 [IQR, 0-1.0]).
None of the patients underwent nasal polyp surgery during the study. According to the Global Evaluation of Treatment Effectiveness, 18 of 21 patients were responders (response rate, 85.7%), whereas 3 of 21 were nonresponders (see Fig E1 in this article's Online Repository at www.jacionline.org). Omalizumab was discontinued by 3 of the 21 patients, and all 3 were nonresponders. The primary reason for discontinuation was high out-of-pocket treatment costs relative to efficacy. Baseline characteristics of responders and nonresponders are presented in Table E2 in this article's Online Repository at www. jacionline.org. Before omalizumab treatment, systemic corticosteroid doses and visual analog scale scores for anterior rhinorrhea and anosmia were significantly lower in nonresponders, implying that this subset of patients had less severe disease. Table I presents urine biomarker concentrations, peripheral blood eosinophil counts, respiratory function, nasal and asthma-related symptom scores, the number of exacerbations and hospitalizations, and daily corticosteroid doses assessed before and after omalizumab treatment. Omalizumab was associated with a marked reduction in urinary concentrations of LTE 4 (76.2%; P < .001) and PGD 2 M (89.0%; P 5 .002) ( Fig 1) . The number of exacerbations and hospitalizations, daily doses of systemic corticosteroid, and all nasal and asthmarelated symptom scores were also significantly reduced. Unexpectedly, rapid symptomatic improvement occurred in 11 of 21 patients (52.4%) within the first week of omalizumab treatment. Furthermore, all 18 responders experienced symptomatic improvement within the 3-month treatment period.
To the authors' knowledge, this is the first report to demonstrate that omalizumab displayed rapid clinical effectiveness and inhibited mast cell activation and leukotriene overproduction in AERD. Gevaert et al 10 documented the clinical efficacy of omalizumab for nasal polyps with comorbid asthma, 10 which may be attributed to suppression of local tissue IgE. Our previous study demonstrated a significant decrease in urinary LTE 4 concentrations after surgery for nasal polyposis in patients with AERD. 11 Because omalizumab reduces the expression of high-affinity IgE Fc receptors on mast cells, 5, 12 it may suppress mast cell activation. In this report, omalizumab treatment ameliorated both upper and lower respiratory tract symptoms, with a significant reduction in urinary LTE 4 and PGD 2 M concentrations, suggesting that omalizumab may stabilize AERD by suppressing mast cell activation and eosinophilrelated inflammation. Furthermore, no moderate-to-severe adverse events such as anaphylaxis occurred.
Limitations of this study include the non-placebo-controlled and nonrandomized design. Also, it was unclear whether reductions in urinary LTE 4 and PGD 2 M concentrations were direct or indirect effects of omalizumab, in addition to the lack of data on PGD 2 M concentration for 8 patients.
In conclusion, omalizumab produced rapid and significant clinical effectiveness in patients with severe AERD who continued treatment for at least 12 months, and induced a remarkable reduction in urinary LTE 4 and PGD 2 M concentrations. Omalizumab may be a potential therapeutic approach for AERD. Prospective, multicenter, randomized, double-blind, and placebo-controlled studies are needed to verify the effectiveness of omalizumab against AERD. §VAS incorporates quantitative and objective measures to assess the severity of asthma and nasal symptoms as well as the efficacy of treatment. VAS scores ranged from ''not at all bothersome'' (0 cm) to ''extremely bothersome'' (10 cm). 
Preserved effector functions of human ORAI1-and STIM1-deficient neutrophils
To the Editor:
The endoplasmic reticulum (ER) Ca 21 sensor stromal interaction molecule 1 (STIM1) and the plasma membrane protein ORAI1, which forms the pore of the Ca 21 release-activated Ca 21 (CRAC) channel, are the core components of storeoperated calcium entry (SOCE). SOCE is an essential pathway of lymphocyte activation, where engagement of immunostimulatory receptors triggers Ca 21 release from the ER through inositol 1,4,5 trisphosphate formation. STIM1 and STIM2 subsequently induce opening of CRAC channels, which are composed of ORAI proteins (ORAI1-ORAI3).
Inherited mutations in ORAI1 or STIM1 genes, which abolish SOCE, cause a combined immunodeficiency syndrome accompanied by various nonhematopoietic manifestations. 1 Whereas the T-cell defect is well established as a key mechanism mediating the immunophenotype of SOCE-deficient patients, the contribution of dysfunctional innate immunity to the broad susceptibility to infections in affected patients is unclear. In particular, data on human polymorphonuclear neutrophils (PMNs) derived from SOCE-deficient patients are lacking. 2 Studies in mice and in human neutrophil-like cell lines suggest a substantial role for SOCE in antimicrobial PMN functions, including phagocytosis, degranulation, and superoxide (reactive oxygen species [ROS]) production. 3, 4 In contrast, other reports implicate non-SOCE mechanisms, such as receptor-operated Ca 21 entry, which is directly mediated by cell-surface receptors and independent of ER stores, as important mediators of PMN activation. 5 A more detailed understanding of SOCE in PMN function is of obvious importance both for understanding the susceptibility to the broad spectrum of microorganisms in patients with SOCE deficiency and because SOCE inhibition in PMNs has been proposed as an anti-inflammatory treatment strategy.
We analyzed Ca 21 signals and effector functions in PMNs from 2 patients with loss-of-function mutations in ORAI1 and STIM1 genes. Surprisingly, and in contrast to T cells, Ca 21 influx was only mildly reduced in ORAI1-and STIM1-deficient PMNs, and detailed studies did not reveal overt defects in PMN function. Accordingly, in contrast to mice, STIM1 and ORAI1 do not appear to be critical for various effector functions of human PMNs.
Methodically, human PMNs were isolated from EDTA blood by means of Biocoll (Biochrom, Berlin, Germany) density gradient centrifugation. Intracellular Ca 21 mobilization was measured by using flow cytometry after labeling with Indo-1 (Invitrogen, Grand Island, NY) and stimulation with formylated methionyl-leucyl-phenylalanine (fMLP; 100 mmol/L), heatfixed streptococci (10 8 /mL), ionomycin (2 mmol/L), or thapsigargin (1 mmol/L). The functional PMN assays (adhesion, chemotaxis, IL-8 production, and ROS formation) were described earlier. 6 Phagocytosis of fluorophore-stained and heat-fixed streptococci was measured by means of flow cytometry after PMN fixation with paraformaldehyde and trypan blue quenching. More details are provided in the Methods section and Table E1 in this article's Online Repository at www.jacionline.org.
Informed consent was obtained from the patients' families in accordance with the Declaration of Helsinki and Institutional Review Board approval from the University of Freiburg Ethics Committee.
First, we compared expression levels of ORAI and STIM homologues between PMNs, B lymphocytes, and T lymphocytes by using publicly available RNA sequencing data from healthy subjects. 7 ORAI1 and STIM1 were similarly expressed in PMNs and lymphocytes. Moreover, mRNA levels of the different ORAI and STIM homologues are comparable across leukocyte subsets (see Fig E1 in this article's Online Repository at www. jacionline.org).
FIG E1. Physicians' Global Evaluations of Treatment Effectiveness (GETE)
at study end. GETE was used to assess control of asthma symptoms in response to the omalizumab treatment, as excellent (complete control), good (marked improvement), moderate (discernible, but limited improvement), poor (no appreciable change), or worsening. Patients with an ''excellent'' or ''good'' response were classified as responders, whereas those with a ''moderate,'' ''poor,'' or ''worsening'' response were classified as nonresponders. E1-E3 
